Drug Prevention of Atrial Fibrillation: Are Novel Agents More Effective Than the Old Ones?

  • T. Van Noord
  • I. C. Van Gelder
  • H. J. G. M. Crijns
Conference paper


This report concerns paroxysmal and persistent atrial fibrillation (AF). Paroxysmal AF usually occurs in short episodes which terminate spontaneously. By contrast, persistent AF does not self-terminate and needs electrical cardioversion for restoration of sinus rhythm [1]. Cardioversion for persistent AF is in general successful. However, the Achilles’ heel in the treatment of both paroxysmal and persistent AF is arrhythmia recurrence. It should be kept in mind that restoration of sinus rhythm, either chemically or electrically, should only be attempted after adequate treatment of the underlying disease. The present review will deal with prevention of AF, focusing on new antiarrhythmic (Vaughan-Williams class III) drugs, recently discovered beneficial effects of conventional antiarrhythmic drugs, and alternative medical treatment strategies.


Atrial Fibrillation Sinus Rhythm Antiarrhythmic Drug Atrial Flutter Persistent Atrial Fibrillation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gallagher MM, Camm J (1998) Classification of atrial fibrillation. Am J Cardiol 82:18N–28NPubMedCrossRefGoogle Scholar
  2. 2.
    Anderson JL, Gilbert EM, Alpert BL, Hernthorn RW, Waldo AL, Bhandari AK, Hawkinson RW, Pritchett ELC (1989) Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. Circulation 80:1557–1570PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson JL, Platt ML, Guarnieri T, Fox TL, Maser MJ, Pritchett ELC, and the Flecainide Supraventicular Tachycardia Study Group (1994) Flecainide acetate for paroxysmal supraventricular arrhythmias. Am J Cardiol 74:578–584PubMedCrossRefGoogle Scholar
  4. 4.
    Van Wijk LM, Den Heijer P, Crijns HJGM, Van Gilst WH, Lie KI (1989) Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 13:32–36PubMedCrossRefGoogle Scholar
  5. 5.
    UK Propafenone PSVT Study Group (1995) A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 92:2550–2557Google Scholar
  6. 6.
    Naccarelli GV, Dorian P, Hohnloser SH, Coumel P, for the Multicenter Atrial Fibrillation Group (1996) Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 77:53A–59APubMedCrossRefGoogle Scholar
  7. 7.
    Reimold SC, Cantillon CO, Friedman PL, Antman EM (1993) Propafenone versus Sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 71:558–563PubMedCrossRefGoogle Scholar
  8. 8.
    Horowitz LN, Spielman SR, Greenspan AM, Mintz GS, Morganroth J, Brown R, Brady PM, Kay HR (1985) Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 66:366–367Google Scholar
  9. 9.
    Tieleman RG, Van Gelder IC, Crijns HJGM, De Kam PJ, Van den Berg MP, Haaksma J, Van der Woude HJ, Allessie MA (1998) Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol 31:167–173PubMedCrossRefGoogle Scholar
  10. 10.
    Van Gelder IC, Crijns HJGM, Tieleman RG, Brügemann J, De Kam PJ, Verheugt FWA, Lie KI (1996) Value and limitation of electrical cardioversion in patients with chronic atrial fibrillation - importance of arrhythmia risk factors and oral anticoagulation. Arch Intern Med 156:2585–2592PubMedCrossRefGoogle Scholar
  11. 11.
    Crijns HJGM, Gosselink ATM, Van Gelder IC, Wiesfeld ACP, Van den Berg MP, Tuininga YS, Lie KI (1992) Drugs after cardioversion to prevent relapses of chronic atrial fibrillation. In: Kingma JH, van Hemel NM, Lie KI (eds) Atrial fibrillation, a treatable disease? Kluwer Academic, Dorchecht, pp 105–148CrossRefGoogle Scholar
  12. 12.
    Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC (1990) Efficacy and safety of quinidine therapy for maintenance of sinus rhythm. A meta-analysis of randomized control trials. Circulation 82:1106–1116PubMedCrossRefGoogle Scholar
  13. 13.
    Carlsson J, Tebbe U, Rox J, Harmjanz D, Haerten K, Neuhaus KL, Seidel F, Niederer W, Miketic S, for the ALKK Study group (1996) Cardioversion of atrial fibrillation in the elderly. Am J Cardiol 78:1380–1384PubMedCrossRefGoogle Scholar
  14. 14.
    Gosselink ATM, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld ACP, Lie KI (1992) Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 32:3289–3293CrossRefGoogle Scholar
  15. 15.
    Kuehlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA (1998) Use of metoprolol CR to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized double-blind placebo-controlled study. Circulation 98:I–633 (abstr)Google Scholar
  16. 16.
    Vos MA, Golitsyn SR, Stangl K, Ruda MY, Van Wijk LV, Harry JD, Perry KT, Touboul P, Steinbeck G, Wellens HJ (1998) Superiority of Ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 79:568–575PubMedGoogle Scholar
  17. 17.
    Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, Van der Lugt JT (1996) Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide repeat dose study investigators. Circulation 94:1613–1621PubMedCrossRefGoogle Scholar
  18. 18.
    Singh SN, Berk MR, Yellen LG, Zoble RG, Haley JA, Abrahamson D, Satler CA (1997) Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: a multicenter study. Circulation 96:I–383 (abstr)Google Scholar
  19. 19.
    Nattel S, Liu L, St-Georges D (1998) Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 37:627–635PubMedCrossRefGoogle Scholar
  20. 20.
    Pritchett E, Page R, Conolly S, Marcello S, Schnell D, Wilkinson W (1998) Azimilide treatment of atrial fibrillation. Circulation 98:I–633 (abstr)Google Scholar
  21. 21.
    Karam R, Marcello S, Brooks RP, Corey AE, Moore A (1998). Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol 81:40D–46DPubMedCrossRefGoogle Scholar
  22. 22.
    Singh BN (1999) Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 10:283–301PubMedCrossRefGoogle Scholar
  23. 23.
    Wijffels MCEF, Kirchhof CJHJ, Dorland R, Allessie MA (1995) Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92:1954–1968PubMedCrossRefGoogle Scholar
  24. 24.
    Tieleman RG, De Langen C, Van Gelder IC, De Kam PJ, Grandjean J, Bel KJ, Wijffels MCEF, Allessie MA, CrijnsHJGM (1997) Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 95:1945–1953PubMedCrossRefGoogle Scholar
  25. 25.
    Daoud EG, Knight BP, Weiss R et al (1997) Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation 96:1542–1550PubMedCrossRefGoogle Scholar
  26. 26.
    Tieleman RG, Gosselink AT, Crijns HJGM, Van Gelder IC, Van den Berg MP, De Kam PJ, Van Gilst WH, Lie KI (1997) Efficacy, safety and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 79:53–57PubMedCrossRefGoogle Scholar
  27. 27.
    Natale A, Tomassoni G, Beheiry S, Zimerman L, Kim YH, Pisano E, Leonelli F, Potenza M, Fanelli R (1998) Prospective randomized evaluation of combined therapy with amiodarone and a calcium antagonist for treatment of refractory atrial fibrillation. Circulation 98:I–103 (abstr)Google Scholar
  28. 28.
    Hohnloser SH, Van de Loo A, Baedeker F (1995) Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of Sotalol versus quinidine. J Am Coll Cardiol 26:852–858PubMedCrossRefGoogle Scholar
  29. 29.
    Jackman WM, Friday KJ, Andersen JL, Alliot EM, Clark M, Lazzaro R (1988) The long QT syndrome: a clinical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 31:115–172PubMedCrossRefGoogle Scholar
  30. 30.
    Falk RH (1989) Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 111:107–111PubMedGoogle Scholar
  31. 31.
    Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG, on behalf of the Stroke Prevention in Atrial Fibrillation Investigators (1992) Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 20:527–532PubMedCrossRefGoogle Scholar
  32. 32.
    Carlsson J, Tebbe U Rox J, Harmjanz D, Haerten K, Neuhaus KL, Seidel F, Niederer W, Miketic S, for the ALKK Study group (1996) Cardioversion of atrial fibrillation in the elderly. Am J Cardiol 78:1380–1384PubMedCrossRefGoogle Scholar
  33. 33.
    Nabar A, Rodriguez LM, Timmermans C, Van de Dool A, Smeets JL, Wellens HJ (1999) Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: observations in four groups having type I atrial flutter with or without associated atrial fibrillation. Circulation 99:1441–1445PubMedCrossRefGoogle Scholar
  34. 34.
    Delfaut P, Saksena S, Prakash A, Krol RB (1998) Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol 32:1900–1908PubMedCrossRefGoogle Scholar
  35. 35.
    Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M (1996) Effect of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: placebo controlled study. J Am Coll Cardiol 28:700–706PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • T. Van Noord
    • 1
  • I. C. Van Gelder
    • 1
  • H. J. G. M. Crijns
    • 1
  1. 1.Department of Cardiology, Thorax CenterUniversity Hospital GroningenThe Netherlands

Personalised recommendations